NAYA Biosciences, Inc (NAYA) - Total Liabilities
Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) has total liabilities worth $33.70 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of NAYA Biosciences, Inc to track the company's year-over-year net asset growth rate.
NAYA Biosciences, Inc - Total Liabilities Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc's total liabilities have evolved over time, based on quarterly financial data. See NAYA Biosciences, Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
NAYA Biosciences, Inc Competitors by Total Liabilities
The table below lists competitors of NAYA Biosciences, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pensana Rare Earths Plc
LSE:PRE
|
UK | GBX20.79 Million |
|
Tristel
LSE:TSTL
|
UK | GBX11.88 Million |
|
GoldOn Resources Ltd
V:GLD
|
Canada | CA$20.70K |
|
Thrive Tribe Technologies Ltd
AU:1TT
|
Australia | AU$659.69K |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
USA | $7.49 Million |
|
PolyPlank publ AB
ST:POLY
|
Sweden | Skr21.55 Million |
|
Henry Boot PLC
LSE:BOOT
|
UK | GBX208.79 Million |
|
Scout Security Ltd
AU:SCT
|
Australia | AU$11.61 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down NAYA Biosciences, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NAYA Biosciences, Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NAYA Biosciences, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual total liabilities of NAYA Biosciences, Inc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.70 Million | +91.34% |
| 2023-12-31 | $17.61 Million | +275.76% |
| 2022-12-31 | $4.69 Million | +48.54% |
| 2021-12-31 | $3.16 Million | -39.36% |
| 2020-12-31 | $5.20 Million | -5.53% |
| 2019-12-31 | $5.51 Million | +57.33% |
| 2018-12-31 | $3.50 Million | -33.41% |
| 2017-12-31 | $5.26 Million | +7.23% |
| 2016-12-31 | $4.90 Million | +13.08% |
| 2015-12-31 | $4.34 Million | +62.86% |
| 2010-12-31 | $2.66 Million | -24.46% |
| 2009-12-31 | $3.52 Million | +256.73% |
| 2008-12-31 | $988.12K | +530.59% |
| 2007-12-31 | $156.70K | -- |
About NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more